Document Detail

Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma.
MedLine Citation:
PMID:  15040025     Owner:  NLM     Status:  MEDLINE    
AIM: To evaluate long-term effect of ethanol embolization for the treatment of hepatocellular carcinoma (HCC) with severe hepatic arterioportal shunt (APS), compared with Gelfoam embolization. METHODS: Sixty-four patients (ethanol group) and 33 patients (Gelfoam group) with HCC and APS were respectively treated with ethanol and Gelfoam for APS before the routine interventional treatment for the tumor. Frequency of recanalization of shunt, complete occlusion of the shunt, side effects, complications, and survival rates were analyzed between the two groups. RESULTS: The occlusion rate of APS after initial treatment in ethanol group was 70.3%(45/64), and recanalization rate of 1 month after embolization was 17.8%(8/45), and complete occlusion rate was 82.8%(53/64). Those in Gelfoam group were 63.6%(21/33), 85.7%(18/21), and 18.2%(6/33). There were significant differences in recanalization rate and complete occlusion rate between the two groups (P<0.05). The survival rates in ethanol group were 78% at 6 months, 49% at 12 months, 25% at 24 months, whereas those in Gelfoam group were 58% at 6 months, 23% at 12 months, 15% at 24 months. The ethanol group showed significantly better survival than Gelfoam group (P<0.05). In the ethanol group, there was a significant prolongation of survival in patients with monofocal HCC (P<0.05) and Child class A (P<0.05). There were no significant differences in survival rate in the Gelfoam group with regard to the number of tumor and Child class (P>0.05). The incidence rate of abdominal pain during procedure in ethanol group was 82.8%. There was no significant difference in postembolization syndromes between two groups. Procedure-related hepatic failure did not occur in ethanol group. CONCLUSION: Ethanol embolization for patients with HCC and severe APS is efficacious and safe, and may contribute to prolongation of the life span versus Gelfoam embolization.
Ming-Sheng Huang; Qu Lin; Zai-Bo Jiang; Kang-Shun Zhu; Shou-Hai Guan; Zheng-Ran Li; Hong Shan
Related Documents :
17477225 - Diagnosis and treatment of idiopathic normal pressure hydrocephalus.
6825515 - Opto-chiasmatic arachnoiditis in the young.
19816985 - Transcatheter closure of patent ductus arteriosus: experience with a new device.
11146685 - Retrograde transcatheter occlusion of patent ductus arteriosus: preliminary experience ...
9163285 - Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy f...
23806305 - Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyo...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  10     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-03-24     Completed Date:  2004-06-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  825-9     Citation Subset:  IM    
Department of Radiology, The 3rd Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road Guangzhou, 510630 China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arteriovenous Fistula / etiology*,  therapy*
Carcinoma, Hepatocellular / complications*
Ethanol / administration & dosage*
Gelatin Sponge, Absorbable / administration & dosage*
Hemostatics / administration & dosage*
Hepatic Artery
Injections, Intra-Arterial
Liver Neoplasms / complications*
Portal Vein
Reg. No./Substance:
0/Hemostatics; 64-17-5/Ethanol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel ...
Next Document:  Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellul...